JOP20190233A1 - نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون - Google Patents
نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتونInfo
- Publication number
- JOP20190233A1 JOP20190233A1 JOP/2019/0233A JOP20190233A JOP20190233A1 JO P20190233 A1 JOP20190233 A1 JO P20190233A1 JO P20190233 A JOP20190233 A JO P20190233A JO P20190233 A1 JOP20190233 A1 JO P20190233A1
- Authority
- JO
- Jordan
- Prior art keywords
- benzoazepine
- bruton
- analogs
- tyrosine kinase
- inhibiting agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485745P | 2017-04-14 | 2017-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190233A1 true JOP20190233A1 (ar) | 2019-10-02 |
Family
ID=62092333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0233A JOP20190233A1 (ar) | 2017-04-14 | 2017-06-16 | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
Country Status (38)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2678021T3 (es) | 2013-12-11 | 2018-08-08 | Biogen Ma Inc. | Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| EP3866926A1 (en) | 2018-10-15 | 2021-08-25 | Biogen MA Inc. | Crystalline polymorphs of bruton's tyrosine kinase inhibitors |
| US12240838B2 (en) | 2019-05-15 | 2025-03-04 | Biogen Ma Inc. | Inhibiting agents for Bruton's tyrosine kinase |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| CN118804915A (zh) | 2021-11-10 | 2024-10-18 | 渤健马萨诸塞州股份有限公司 | Btk抑制剂 |
| JP2023140319A (ja) | 2022-03-22 | 2023-10-04 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JP2010522241A (ja) | 2007-03-21 | 2010-07-01 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物 |
| CA2701581C (en) | 2007-10-05 | 2016-12-20 | S*Bio Pte Ltd | Pyrimidine substituted purine derivatives |
| CA2716898A1 (en) | 2008-02-27 | 2009-09-03 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
| NZ589843A (en) | 2008-06-27 | 2012-12-21 | Avila Therapeutics Inc | Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8785440B2 (en) * | 2009-09-04 | 2014-07-22 | Biogen Idec Ma, Inc. | Bruton's tyrosine kinase inhibitors |
| US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| SI2734522T1 (sl) | 2011-07-19 | 2019-03-29 | Merck Sharp & Dohme B.V. | 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDI IN 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI kot BTK-INHIBITORJI |
| TWI648273B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（三） |
| WO2014130856A2 (en) | 2013-02-21 | 2014-08-28 | Wayne Rothbaum | Treatment of skeletal-related disorders |
| SG10201901902WA (en) | 2013-10-21 | 2019-04-29 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
| ES2678021T3 (es) | 2013-12-11 | 2018-08-08 | Biogen Ma Inc. | Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología |
| KR102523111B1 (ko) * | 2014-10-06 | 2023-04-18 | 메르크 파텐트 게엠베하 | Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도 |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
-
2017
- 2017-06-16 JO JOP/2019/0233A patent/JOP20190233A1/ar unknown
-
2018
- 2018-04-13 BR BR112019021399-6A patent/BR112019021399A2/pt active Search and Examination
- 2018-04-13 SG SG11201909224Q patent/SG11201909224QA/en unknown
- 2018-04-13 IL IL316713A patent/IL316713A/en unknown
- 2018-04-13 WO PCT/US2018/027415 patent/WO2018191577A1/en not_active Ceased
- 2018-04-13 KR KR1020197032715A patent/KR102607900B1/ko active Active
- 2018-04-13 HR HRP20240361TT patent/HRP20240361T1/hr unknown
- 2018-04-13 PT PT187216320T patent/PT3609886T/pt unknown
- 2018-04-13 CA CA3058774A patent/CA3058774A1/en active Pending
- 2018-04-13 PL PL18721632.0T patent/PL3609886T3/pl unknown
- 2018-04-13 CN CN202311088635.7A patent/CN117567453A/zh active Pending
- 2018-04-13 MA MA50013A patent/MA50013B1/fr unknown
- 2018-04-13 NZ NZ757929A patent/NZ757929A/en unknown
- 2018-04-13 AR ARP180100935A patent/AR111594A1/es not_active Application Discontinuation
- 2018-04-13 SM SM20240166T patent/SMT202400166T1/it unknown
- 2018-04-13 TW TW107112785A patent/TWI790227B/zh active
- 2018-04-13 EP EP18721632.0A patent/EP3609886B1/en active Active
- 2018-04-13 MD MDE20200193T patent/MD3609886T2/ro unknown
- 2018-04-13 EP EP23187919.8A patent/EP4249071A3/en active Pending
- 2018-04-13 US US15/952,505 patent/US10227341B2/en active Active
- 2018-04-13 PE PE2019002016A patent/PE20200740A1/es unknown
- 2018-04-13 HU HUE18721632A patent/HUE066253T2/hu unknown
- 2018-04-13 JP JP2019555961A patent/JP7145874B2/ja active Active
- 2018-04-13 KR KR1020237040706A patent/KR102862996B1/ko active Active
- 2018-04-13 TW TW111149550A patent/TWI846229B/zh active
- 2018-04-13 AU AU2018253209A patent/AU2018253209B2/en active Active
- 2018-04-13 DK DK18721632.0T patent/DK3609886T3/da active
- 2018-04-13 PE PE2024000228A patent/PE20240930A1/es unknown
- 2018-04-13 CR CR20190517A patent/CR20190517A/es unknown
- 2018-04-13 SI SI201831083T patent/SI3609886T1/sl unknown
- 2018-04-13 FI FIEP18721632.0T patent/FI3609886T3/fi active
- 2018-04-13 KR KR1020257031163A patent/KR20250140646A/ko active Pending
- 2018-04-13 ES ES18721632T patent/ES2975769T3/es active Active
- 2018-04-13 IL IL294175A patent/IL294175B2/en unknown
- 2018-04-13 RS RS20240419A patent/RS65386B1/sr unknown
- 2018-04-13 CN CN201880031744.6A patent/CN110621670B/zh active Active
- 2018-04-13 LT LTEPPCT/US2018/027415T patent/LT3609886T/lt unknown
- 2018-04-13 UA UAA201911128A patent/UA127347C2/uk unknown
- 2018-04-13 IL IL269933A patent/IL269933B/en unknown
- 2018-04-13 EA EA201992354A patent/EA201992354A1/ru unknown
- 2018-08-27 US US16/113,455 patent/US10189829B2/en active Active
-
2019
- 2019-04-13 CR CR20230539A patent/CR20230539A/es unknown
- 2019-08-07 US US16/534,540 patent/US10961237B2/en active Active
- 2019-10-10 SA SA519410292A patent/SA519410292B1/ar unknown
- 2019-10-11 MX MX2023000812A patent/MX2023000812A/es unknown
- 2019-10-11 CL CL2019002900A patent/CL2019002900A1/es unknown
- 2019-10-14 PH PH12019502334A patent/PH12019502334A1/en unknown
- 2019-11-12 CO CONC2019/0012571A patent/CO2019012571A2/es unknown
-
2021
- 2021-02-24 US US17/183,702 patent/US11427577B2/en active Active
-
2022
- 2022-07-22 US US17/871,157 patent/US11858926B2/en active Active
- 2022-08-18 AU AU2022218560A patent/AU2022218560B2/en active Active
- 2022-09-20 JP JP2022148866A patent/JP7581294B2/ja active Active
-
2023
- 2023-06-12 ZA ZA2023/06172A patent/ZA202306172B/en unknown
- 2023-06-15 AR ARP230101541A patent/AR129632A2/es unknown
-
2024
- 2024-06-20 AU AU2024204241A patent/AU2024204241A1/en active Pending
- 2024-10-30 JP JP2024190472A patent/JP7778206B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2016009403A (es) | Compuestos heterociclicos. | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| SA518400660B1 (ar) | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| PH12019501639B1 (en) | Jak1 selective inhibitors | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| NZ712341A (en) | A crystalline form of an anxiolytic compound | |
| WO2020232330A8 (en) | Inhibiting agents for bruton's tyrosine kinase | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
| EA201792676A1 (ru) | Ингибиторы jak1 | |
| MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. |